ClinicalTrials.gg
Not yet recruitingNCT04963868TTSRNPUpdated Jul 15, 2021

Timing of Transmural Stent Removal in Necrotizing Pancreatitis

An interventional study of Stent removed by the novel strategy and Stent removed by the conventional strategy in Acute Pancreatitis, Necrotizing Pancreatitis and Walled-Off Necrosis, sponsored by The First Affiliated Hospital of Nanchang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by The First Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Pancreatitis with a site in China — 40 open to participants now, 44 under way, 2 of them phase 3. Pancreatitis · China.

Planned enrollment
33rd of 75
156 · median 110
Started
2022
with 5 others
No phase
48 of 104
16 open now
Primary completion
2024-06
later than 0 of 43 live
Registered
50th of 104
by date
Lead sponsor
7 of 104
The First Affiliated Hospital of Nanchang University

Among the 104 studies in Pancreatitis with a site in China, this one is the 33rd largest by planned enrollment of the 75 interventional ones that give a count, is one of 6 that started in 2022, is one of 48 with no phase, reaches primary completion later than 0 of the 43 other live ones, and was the 50th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

40 of the 104 studies in Pancreatitis with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Pancreatitis with a site in China, or all of them as a file.
02

Study summary

Although metal stents have been widely used in the endoscopic step-up approach for necrotizing pancreatitis, the exact timing of transmural stent removal has not been well studied. In this prospective, open-label, randomized controlled study, we recruited and enrolled consecutive patients with necrotizing pancreatitis undergoing endoscopic transmural necrosectomy. Eligible participants were randomly assigned to case group (a novel strategy in which the stents were removed during the last necrosectomy when the necrosectomy endpoint was achieved) and control group (the conventional strategy in which the stents were removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by imaging). The primary endpoint was the incidence of composite complications within three months of enrollment.

Read the detailed description

Over the last decade, approaches to managing necrotizing pancreatitis have evolved from open surgery to a minimally invasive approach due to the efficacy and lower morbidity and mortality rates of the latter technique. As one of minimally invasive approaches, endoscopic step-up approach, with transmural drainage whenever feasible and subsequent necrosectomy as required, was first described in 1996 and has evolved to first-line therapy for symptomatic necrotizing pancreatitis. However,The exact timing of transmural stent removal has not been well studied. The conventional strategy for stent removal in the published guidelines has been that patients should undergo follow-up imaging and stent removal at 4-8 weeks if walled-off necrosis has resolved. Here, we introduced a novel strategy in which the stents were removed during the last necrosectomy when the endpoint of endoscopic transmural necrosectomy was achieved, that was, the necrotic tissue was nearly completely removed, and the pink granulation tissue lining the wall was uncovered. Compared to the conventional strategy, the novel strategy avoided one endoscopy procedure. The present study is the first prospective, open-label, randomized controlled study to investigate the efficacy and safety of the novel strategy. We recruited and enrolled consecutive patients with necrotizing pancreatitis undergoing endoscopic transmural necrosectomy. Eligible participants were randomly assigned to case group (a novel strategy in which the stents were removed during the last necrosectomy when the necrosectomy endpoint was achieved) and control group (the conventional strategy in which the stents were removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by imaging). The primary endpoint was the incidence of composite complications within three months of enrollment.

03

Conditions studied

  • Acute Pancreatitis
  • Necrotizing Pancreatitis
  • Walled-Off Necrosis

Keywords

  • Necrotizing pancreatitis
  • Endoscopic transmural necrosectomy
  • Lumen-apposing metal stent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with necrotizing pancreatitis according to the 2012 Atlanta classification criteria;
  2. Patients aged between 18 and 65 years;
  3. Patients who signed the ;

Exclusion criteria

Exclusion Criteria:

  1. Patients without transmural stent placement;
  2. Patients with transmural plastic stent not metal stent placement before enrollment;
  3. Patients who underwent endoscopic transmural necrosectomy in other hospitals before admission;
  4. Patients complicated with chronic pancreatitis;
  5. Patients complicated with pancreatic tumor;
  6. Pregnant or lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    The novel strategy group

    The stents were removed during the last necrosectomy when the endpoint of necrosectomy was achieved

    Procedure: Stent removed by the novel strategy

  • Active comparator
    The conventional strategy group

    The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image

    Procedure: Stent removed by the conventional strategy

Interventions

  • ProcedureStent removed by the novel strategy

    The stent was removed during the last necrosectomy when the endpoint of necrosectomy was achieved;

  • ProcedureStent removed by the conventional strategy

    The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image.

06

What researchers measure

Primary outcomes

  1. The incidence of composite complications

    The composite complications included new-onset organ failure or systemic complications、new-onset infectious pancreatic necrosis、abdominal or gastrointestinal bleeding, intestinal fistula, stent occlusion and stent migration.

    Time frame: 3 months

Secondary outcomes

  1. The incidence of technical success

    Technical success was defined by stent removed successfully.

    Time frame: 3 months

  2. The incidence of clinical success

    Clinical success was defined as nearly completely resolution or \<2 cm of collection assessed by image at the three-month follow-up without additional open surgery or death.

    Time frame: 3 months

  3. The number of endoscopic transmural necrosectomy sessions

    Total sessions of patients undergoing endoscopic transmural necrosectomy.

    Time frame: 3 months

  4. The number of additional endoscopic transmural necrosectomy sessions after stent removal

    Additional sessions of patients undergoing endoscopic transmural necrosectomy. after stent removal.

    Time frame: 3 months

  5. Length of stent placement

    The duration time from stent placement to stent removal.

    Time frame: 3 months

  6. The incidence of open surgery

    The incidence of patients needing open surgery after minimally invasive treatment.

    Time frame: 3 months

  7. All-cause mortality

    The mortality whatever the cause is.

    Time frame: 3 months

  8. Length of hospital stay

    The length of hospital stay due to necrotizing pancreatitis.

    Time frame: 3 months

  9. The incidence of readmission

    The incidence of readmission after index discharge due to pancreatitis related problems.

    Time frame: 12 months

  10. The hospital cost

    The hospital cost during hospitalization.

    Time frame: 3 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2022; primary completion for Jun 2024, 29 months later.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 29 months is close to that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jul 15, 2021
StartEst.
Jan 1, 2022
Primary completionEst.
Jun 1, 2024
CompletionEst.
Dec 1, 2025
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04963868
Lead sponsor
The First Affiliated Hospital of Nanchang University
Responsible party
Lingyu Luo (Physician-in-charge, The First Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Jul 15, 2021
Start date
Jan 1, 2022 (estimated)
Primary completion
Jun 1, 2024 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jul 15, 2021

Study contacts

Yin Zhu, PhD
Contact
zhuyin27@sina.com
86-791-88692507
Yin Zhu, PhD
principal investigator · The First Affiliated Hospital of Nanchang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion